ProbioMax Daily DF 60 C

ProbioMax Daily DF 60 Capsules by Xymogen

ProbioMax Daily DF 60 capsules is a gastrointestinal health supplement designed by Xymogen, a brand that prioritizes researched formulas and high-quality.* It is a probiotic that consists of 4 different bacteria strains—it may support your bowel function, lactose digestion and immunity.*

Who Should Consider ProbioMax Daily DF 60c?

ProbioMax Daily DF 60c may support your health if you:

• suffer from lactose intolerance*
• want to support your GI tract*
• are on antibiotics*

ProbioMax Daily DF 60c—Effects

ProbioMax Daily DF 60 capsules may have the following effects:

• maintaining a healthy intestinal microecology*
• supporting bowel regularity*
• promoting lactose digestion*
• improving natural immune response*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about ProbioMax Daily DF 60c.

Recommendation: 
Xymogen suggests taking one ProbioMax Daily DF capsule with water daily, or as directed by your healthcare professional.

Serving Size: 1 Capsule
Servings Per Container: 60 

Amount Per Serving:
Proprietary Blend  174 mg (15 Billion CFU^†)
Lactobacillus acidophilus La-14^S1
Bifidobacterium longum Bl-05^S2
Lactobacillus plantarum Lp-115^S3
Bifidobacterium lactis HN019^S4    50 mg (15 Billion CFU^†)

Other Ingredients: Microcrystalline cellulose, capsule (hypromellose, gellan gum, and water), stearic acid, magnesium stearate, and silica.

Does Not Contain: Wheat, gluten, soy, animal and dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.

Caution:
Consult your healthcare professional prior to use. Individuals taking medication should discuss potential interactions with their healthcare professional.

Storage:
No refrigeration necessary. Keep closed in a cool, dry place out of reach of children.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Trademarks:
† Colony-Forming Unit
S1. La-14^® is a registered trademark of DuPont.
S2. Bl-05^™ is a trademark of DuPont.
S3. Lp-115^® is a registered trademark of DuPont.
S4. HOWARU^® and the HOWARU® logo are registered trademarks of DuPont or its affiliates. HN019^® is a registered trademark of Fonterra™ Limited and is licensed to DuPont Nutrition Biosciences.

LEGAL NOTICE: Xymogen's Exclusive Professional Formulas are available through select licensed health care professionals. The Internet Sale and Discounting of XYMOGEN formulas are strictly prohibited. covenanthealthproducts.com makes XYMOGEN formulas available only to patients of our clinic. If you are a patient of covenanthealthproducts.com, you may inquire about XYMOGEN by calling (800) 627-6518

References:

1. Ahmed, M., Prasad, J., Gill, H., et al. (2007). Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. Journal of Nutrition, Health and Aging, 11(1), 26-31. [PMID: 17315077]
2. Abratt, V. R., & Reid, S. J. (2010). Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease. Advances in Applied Microbiology, 72, 63-87. [PMID: 20602988]
3. Collado, M. C., Meriluoto, J., & Salminen, S. (2007). Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Letters in Applied Microbiology, 45(4), 454-460. [PMID: 17897389]
4. Ding, W. K., & Shah, N. P. (2007). Acid, bile, and heat tolerance of free and microencapsulated probiotic bacteria. Journal of Food Science, 72(9), M446-50. [PMID: 18034741]
5. Gopal, P., et al. (2003). Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. Nutrition Research, 23, 1313-1328. Retrieved from http://www.daniscosupplements.com/clinical-study-bibliography.html (Accessed June 24, 2011).
6. Greene, J. D., & Klaenhammer, T. R. (1994). Factors involved in adherence of lactobacilli to human Caco-2 cells. Applied and Environmental Microbiology, 60(12), 4487-4494. [PMID: 7811085]
7. Kleeman, E. G., & Klaenhammer, T. R. (1982). Adherence of Lactobacillus species to human fetal intestinal cells. Journal of Dairy Science, 65(11), 2063-2069. [PMID: 7153393]
8. Masood, M. I., Qadir, M. I., Shirazi, J. H., et al. (2011). Beneficial effects of lactic acid bacteria on human beings. Critical Reviews in Microbiology, 37(1), 91-98. [PMID: 21162695]
9. Sazawal, S., Dhingra, U., Hiremath, G., et al. (2010). Effects of Bifidobacterium lactis HN019 and prebiotic oligosaccharide added to milk on iron status, anemia, and growth among children 1 to 4 years old. Journal of Pediatric Gastroenterology and Nutrition, 51(3), 341-346. [PMID: 20601905]
10. Shu, Q., Lin, H., & Rutherfurd, K. J. (2000). Dietary Bifidobacterium lactis (HN019) enhances resistance to oral Salmonella typhimurium infection in mice. Microbiology and Immunology, 44(4), 213-222. [PMID: 10832963]
11. Turroni, S., Vitali, B., Bendazzoli, C., et al. (2007). Oxalate consumption by lactobacilli: Evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in Lactobacillus acidophilus. Journal of Applied Microbiology, 103(5), 1600-1609. [PMID: 17953571]
12. Vanderpool, C., Yan, F., & Polk, D. B. (2008). Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflammatory Bowel Diseases, 14(11), 1585-1596. [PMID: 18623173]
13. Waller, P. A., Gopal, P. K., Leyer, G. J., et al. (2011). Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scandinavian Journal of Gastroenterology, 46(9), 1057-1064. [PMID: 21663486]